HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env(1), in the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nature
Autori principali: Scheid, Johannes F., Horwitz, Joshua A., Bar-On, Yotam, Kreider, Edward F., Lu, Ching-Lan, Lorenzi, Julio C. C., Feldmann, Anna, Braunschweig, Malte, Nogueira, Lilian, Oliveira, Thiago, Shimeliovich, Irina, Patel, Roshni, Burke, Leah, Cohen, Yehuda Z., Hadrigan, Sonya, Settler, Allison, Witmer-Pack, Maggi, West, Anthony P., Juelg, Boris, Keler, Tibor, Hawthorne, Thomas, Zingman, Barry, Gulick, Roy M., Pfeifer, Nico, Learn, Gerald H., Seaman, Michael S., Bjorkman, Pamela J., Klein, Florian, Schlesinger, Sarah J., Walker, Bruce D., Hahn, Beatrice H., Nussenzweig, Michel C., Caskey, Marina
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034582/
https://ncbi.nlm.nih.gov/pubmed/27338952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature18929
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi